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Background: The changes in body composition markers (weight, fat mass, lean mass, and BMI) over time can be 
associated with TB treatment outcome among HIV-infected patients. The aim of this study was to investigate whether 
changes in fat mass and lean mass were associated with the treatment response among patients with HIV infection and 
pulmonary tuberculosis. 
Materials and Methods: This was a prospective cohort study. Data from HIV-infected patients commencing TB 
therapy were analyzed. This included body weight measurement using bioimpedance equipment at baseline, one 
month, and two months after starting TB treatment. 
Results: The study was conducted in 125 patients, 17 patients (13.6%) died during treatment, of which 5 died during 
the first month of treatment, 4 during the second month and 8 after the second month. The group of patients with good 
response, increased their weight by 1.3 kg (p <0.001) at the end of the first month of TB treatment and 2.6 kg in the 
second month (p <0.001), and body fat increase was 1.2 Kg (p <0.001) and 2.3 kg (p <0.001), the first and second 
month respectively. The group of patients who died had lost 2.1 kg fat mass after the first month (p <0.001) and 3.7 kg 
in the second month (p <0.001). 
Conclusions: Our results show that the weight change during TB treatment (increased fat mass) helps us predict 
therapeutic response. Weight loss during the first month of starting therapy should be evaluated thoroughly to identify 
the probable cause of treatment failure. 
 





Despite the existence of adequate treatment, tuberculosis (TB) is one of the leading causes of respiratory 
morbidity and mortality among HIV-infected people worldwide, accounting for 44% of all deaths related to AIDS 
(Ackah et al., 1995). In 2012 around 13% of the 8.7 million TB cases were positive for HIV (UNAIDS 2013), in 
addition, HIV infection increases the risk of acquiring M. tuberculosis primary infection between 2.2 and 5.5 times 
(Crampin et al., 2010; Sonnenberg et al., 2001), and the risk of TB reactivation up to 20 times. As a result, every year, 
around 5-15% of HIV-infected individuals experience M. tuberculosis reactivation (Pawlowski et al., 2012).  
Many countries, including Peru, the patients’ weight is checked every month during TB treatment to assess 
therapy response (Bernabe et al., 2011; Ott et al., 1993). Weight loss is an important sign of active disease in TB, and 
can be considered a marker of disease severity as different cytokines and inflammatory components are responsible for 
hyporexia and hypercatabolism (Schwenk et al., 2000; Zhang et al., 1997). Moreover, weight loss during the intensive 
phase of treatment is considered a risk factor for therapy failure (Schon et al., 2011).  
Several methods of measuring body weight have been described. Bioelectrical impedance analysis (BIA) is 
one technique that also determines body composition. BIA measures the impedance of water, facilitating evaluation of 
total body water, and hencing body fat and muscle mass. It has been validated in many diseases (Dioum et al., 2005; 
Zhou et al., 2011); however, there is scarce literature assessing the use of this technique in HIV and TB coinfected 
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populations (Mupere et al., 2010; Schwenk et al., 1999). Moreover, to the best of our knowledge, the use of 
bioelectrical impendace has not been evaluated to predict tuberculosis treatment outcome among HIV and TB 
coinfected individuals. 
Therefore, we aimed to assess whether changes in BIA markers, including weight, total body water, fat mass, 
lean mass (non-fat mass), and BMI, over time were associated with treatment outcome (i.e. deaths during treatment) 
among patients with HIV infection and pulmonary tuberculosis.  
 
Materials and Methods 
Study design and setting 
 
A longitudinal prospective cohort study was conducted by enrolling consecutive HIV-infected patients with 
confirmed TB diagnosis (MINSA 2013). Participants were recruited from two tertiary-level hospitals in Lima, Peru 
(Hospital Nacional Dos de Mayo and Hospital Nacional Daniel Alcides Carrion) from January 2012 to October 2014.  
 
Study population and selection criteria 
 
HIV-infected patients, aged ≥15 years, with or without highly-active anti-retroviral therapy (HAART) who 
had been newly diagnosed with pulmonary tuberculosis (aputum smear positive for acid-fast bacilli (AFB) and/or 
culture-positive) were asked to participate in the study. Patients who had been taking TB treatment for two weeks or 
more were excluded from the study. 
The outcome of interest was body composition assessed by five different anthropometric markers. The TBF-
300A body composition analyzer (Multi-Frequency Tanita Corporation, Tokyo, Japan), a portable device was used to 
measure weight (Kg), fat mass (Kg), fat-free mass (or lean mass, Kg), total body water (Kg), and BMI (Kg/m2). These 
markers were measured with a precison of 0.1 Kg according to manufacturer’s guidelines (TANITA 2012). As the 
main aim of the study was to predict overall treatment outcome, all of these proposed markers were evaluated at the 
start of treatment (baseline) and monthly, measuring only during the intensive phase of TB treatment (i.e. during the 
first two months of therapy).   
The main exposure was overall mortality, defined as those patients who died during TB treatment considering 
the total time of therapy (i.e. six months).  
Other variables of interest included in the analysis were sex, age (in years), receiving HAART during TB 
treatment (yes/no), self-report of previous TB prophylaxis with isoniazid (yes/no) and presence of other co-morbidities 
including other infectious diseases during treatment. In addition, CD4 count (<200 and ≥200 cells/mm3), viral load (log 
transformed to account for skewed distribution), drug susceptibility, i.e. MDR-TB (yes/no), defined according to 





After assessing selection criteria, suitable patients were invited to participate. All the patients gave their 
consent. Patients were requested to answer a detailed questionnaire regarding their sociodemographic backgrounds as 
well as their HIV and TB history. After completing the questionnaires, and before taking body composition measure, 
patients were asked to empty their bladder and bare their feet to guarantee adequate results. They were then asked to 
stand on the metal pads of the BIA device with the arms hanging on each side as per manufacturer’s instructions 
(TANITA 2012). Their weight, BMI, fat mass, lean mass and total body water composition were automatically 
calculated by the device. Data regarding CD4 level and viral load were obtained from their clinical records, as routine 
management of HIV-infected patients requires these results before starting treatment. In addition, M. tuberculosis drug 
susceptibility was also evaluated as part of the National Tuberculosis Control and Prevention Strategy (MINSA 2013). 
Follow-up assessments were performed at the end of every month of therapy, as per the National Tuberculosis Control 
and Prevention Strategy’s schedule. Under the Directly Observed Treatment, Short-Course Strategy (DOTS), patients 
are weighed routinely using a traditional scale. Instead of this technique, patients were evaluated using the body 
composition analyzer. At the completion of the study, each patient’s TB treatment outcome data were collected from 




This study was approved by the Institutional Ethical Committee of the Universidad Peruana Cayetano Heredia, 
Lima, Peru, number 16-2014. In addition, each of the ethical committees of the hospitals also approved the study before 
beginning the activities. This study obtained the patients’ consent before research activities and their confidentiality 




Microsoft Excel for Windows was utilized for double data entry process. STATA version 13.0 for Windows 
(STATA Corp, College Station, TX, US) was used for analysis.  
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Initially, a description of demographic and clinical characteristics was tabulated according to mortality. 
Categorical variables were compared using Chi squared or Fisher’s exact test as appropriate, whereas numerical 
variables were compared using the Student’s t test. In addition, mean and standard deviation (SD) of BIA 
anthropometric markers, in Kg, were calculated for each outcome group according to the month of follow-up. Finally, a 
random effects model was fitted to estimate average weight trends for patients who died and those who survived 
(Hardin et al., 2003). An a priori model - used in other publications (Bernabe et al., 2011; Chung et al., 2014)-  was 
used to estimate the variation of the proposed anthropometric markers over time: 
 
OutcomeTTOutcomeY ijijij ... .3210    
 
Where Yij is the mean of any of the proposed anthropometrical markers (i.e. weight, fat mass, lean masn, total body 
water, or BMI) in kg in patient “i” at time “j”; β0 is the intercept, for example, fat mass in kilograms among those who 
survived at baseline; β1 is the difference in the selected anthropometrical marker in patiens who died compared to those 
who survived; β2 quantifies the change of selected marker between baseline and one selected month for participants 
who survived; and the sum of β2 and β3 (interaction term) represents the variation in the selected marker between 
baseline and one month for participants who died (Fitzmaurice et al., 2004; Hanley et al., 2003). Robust standard errors 
were used to handle misspecification of variance correlation functions. Potential confounders included in the model 
were age, sex, drug susceptibility, and CD4 count. We decided for this group of variables as many of them were highly 
correlated, especially those related to HIV prognosis (i.e.CD4 count, viral load, HAART, and co-morbidities). 
 
Results 
Population characteristics at baseline 
 
A total of 134 pulmonary tuberculosis and HIV-infected patients who started TB treatment during the study 
period were contacted; however, 9 were excluded from further analyses (4 abandoned therapy, 3 changed treatment 
regimen, and 2 were transferred to another facility). Therefore, 125 patients were analyzed.  86 (68.8%) were male 
patients and mean age was 36.9 (SD: 13.5, range 15 – 88) years. The characteristics of the population according to 
treatment outcome status are shown in Table 1. There was no significant difference in age or sex between the two 
groups.  All of the patients who died during treatment had a CD4 count <200 cells/mm3, whereas those who survived, 
one third, had a CD4 count greater than or equal to 200 cells/mm3. Viral load was higher in patients who died during 
treatment. 
 
Table 1: Characteristics of the study population at baseline according to tuberculosis treatment outcome 
 Survived to 6 months 
Died during TB 
treatment p-value* 
 (n = 108) (n = 17) 
Sex    
Female 32 (82.1%) 7 (17.9%) 0.40 
Male 76 (88.4%) 10 (11.6%)  
Age    
Mean (SD) 35.7 (15.2) 42.2 (15.6) 0.10 
CD4 count    
< 200 cells/mm3 72 (66.7%) 15 (100%) 0.005 
≥ 200 cells/mm3 36 (33.3%) 0 (0.0%)  
Viral load (Log)    
Mean (DE) 10.8 (3.6) 13.2 (1.3) 0.01 
Drug susceptibility    
No MDR 95 (88.0%) 13 (76.5%) 0.39 
MDR-TB 11 (10.2%) 3 (1.8%)  
HAART during TB treatment    
No  82 (75.9%) 8 (7.4%) <0.001  
Yes 4 (3.7%) 9 (8.3%)  











SD = standard deviation = multidrug-resistant TB 
* Fisher's exact test was used to calculate the p-value in the case of categorical variables, and Student t test for 
numerical variables. &Isoniazid 
 
Death and variation over time of BIA anthropometric markers 
 
Seventeen (13.6%) participants died during TB treatment: 5 deaths occurred in the first month, 4 in the second 
month, and 8 after the second month. A detailed description of the variation in selected anthropometric markers is 
shown in Table 2. Almost all of the BIA markers decreased among those who died, with special emphasis on fat mass. 
Nonetheless, lean mass (free-fat mass) was almost constant among those who survived and those who died. 
 






























SD = Standard Deviation; BMI = Body Mass Index 
 
 
Variation of anthropometric markers over time and treatment outcome 
 
Results of crude and adjusted mixed linear models are shown in Table 3. There was no difference in baseline 
anthropometric markers between patients who died and survived; however, the interaction terms in all five markers 
were statistically significant (p<0.001). As a consequence, results suggest that HIV-infected patients who died during 
TB treatment lost 1.8 kg of weight (p<0.001), 0.9 kg of fat mass (p<0.001), and 0.8 kg of lean mass (p = 0.008) at the 
end of the first month of therapy; whereas at the end of the second month, those patients lost 2.8 kg of weight 
(p<0.001), 1.5 kg of fat mass (p<0.001) and 1.3 kg of lean mass (p = 0.03). In contrast, patients who survived, gained 
1.3 kg of weight (p<0.001) and 1.2 kg of fat mass (p<0.001), but not lean mass (p = 0.59) at the end of first month of 
treatment; whereas gained 2.6 kg of weight (p<0.001) and 2.3 kg of fat mass (p<0.001), but not lean mass (p = 0.20) at 
the end of the second month of therapy (Figure 1). Similar results were obtained when body water and body mass index 
were evaluated. 
No  105 (97.2%) 17 (100%) 0.99 
Yes 3 (2.8%) 0 (0.0%)  
Presence of co-morbidity    
No  99 (91.7%) 10 (9.3%) 0.001 
Yes 9 (8.3%) 7 (6.5%)  
 Baseline First month Second month 
 n Mean (SD) n Mean (SD) n Mean (SD) 
Weight (Kg)       
Survived to therapy 
completion  108 55.3 (10.4) 108 56.5 (10.7) 108 57.8 (10.8) 
Died prior to therapy 
completion  17 56.7 (10.5) 12 56.2 (10.3) 8 54.4 (10.6) 
Total body water (Kg)       
Cured 108 33.2 (6.2) 108 33.9 (6.4) 108 34.7 (6.5) 
Died 17 34.0 (6.3) 12 33.7 (6.2) 8 32.6 (6.4) 
Fat mass (Kg)       
Cured 108 9.6 (5.2) 108 10.8 (5.5) 108 11.9 (6.0) 
Died 17 10.5 (5.0) 12 8.2 (2.4) 8 7.9 (2.6) 
Lean mass (Kg)       
Cured 108 45.6 (9.9) 108 45.7 (9.9) 108 45.9 (9.8) 
Died 17 46.1 (9.3) 12 47.9 (9.5) 8 46.5 (9.1) 
BMI (Kg/m2)       
Cured 108 20.9 (3.1) 108 21.4 (3.3) 108 21.9 (3.4) 
Died 17 22.1 (4.5) 12 20.6 (3.7) 8 20.5 (4.3) 
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95%CI = 95% confidence interval  
* Adjusted for age, sex, drug susceptibility and CD4 count. 
 Weight (Kg) Fat mass (Kg) Lean mass (Kg) 
 β (95%CI) p-value β (95%CI ) p-value β (95%CI) p-value 
Crude model       
Intercept 55.3 (53.3; 57.2) < 0.001 9.6 (8.7; 10.6) < 0.001 45.6 (43.8; 47.5) < 0.001 
Dead 1.39 (-3.9; 6.7) 0.61 0.90 (-1.62; 1.43) 0.49 0.49 (-4.25; 5.23) 0.84 
Time (1st month) 1.25 (1.00; 1.50) < 0.001 1.18 (0.92; 1.43) < 0.001 0.08 (-0.24; 0.40) 0.64 
Time (2nd month) 2.55 (2.11; 2.99) < 0.001 2.24 (1.86; 2.62) < 0.001 0.31 (-0.15; 0.78) 0.18 
Died * Time (1st month) -3.03 (-3.83; -2.24) < 0.001 -2.17 (-2.57; -1.77) < 0.001 -0.88 (-1.55; -0.21) 0.01 
Died * Time (2nd month) -5.33 (-6.55; -4.12) < 0.001 -3.76 (-4.31; -3.22) < 0.001 -1.59 (-2.99; -0.18) 0.03 
       
Adjusted model*       
Intercept 48.7 (43.2; 54.3) < 0.001 7.8 (4.8; 10.8) < 0.001 40.9 (36.0; 45.8) < 0.001 
Dead 1.94 (-4.36; 8.24) 0.55 -0.68 (-3.11; 1.75) 0.58 2.62 (-2.88; 8.11) 0.35 
Time (1st month) 1.27 (1.01; 1.52) < 0.001 1.18 (0.92; 1.44) < 0.001 0.09 (-0.24; 0.42) 0.59 
Time (2nd month) 2.57 (2.12; 3.01) < 0.001 2.26 (1.87; 2.65) < 0.001 0.31 (-0.16; 0.78) 0.20 
Died * Time (1st month) -3.06 (-3.87; -2.25) < 0.001 -2.12 (-2.54; -1.73) < 0.001 -0.92 (-1.61; -0.24) 0.008 
Died * Time (2nd month) -5.34 (-6.55; -4.13) < 0.001 -3.73 (-4.30; -3.20) < 0.001 -1.59 (-2.98; -0.19) 0.03 
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2a. Weight variation over time* 2b. Fat mass variation over time* 2c. Lean mass variation over time* 
   
Figure 1: Variation over time of selected anthropometric markers: weight (2a), fat mass (2b) and lean mass (2c) during TB 
treatment among HIV-infected patients. * Predicted lines were calculated using random effect models adjusting by age, sex, drug 






This study demonstrated the variation of different anthropometrical markers (i.e. body weight, but also fat mass and other 
BIA markers) during the first two months of tuberculosis treatment among HIV-coinfected patients. Accordingly, these markers 
can potentially predict death among these patients after controlling for potential confounders such as age, sex, drug susceptibility 
and CD4 count: patients with good outcome at the end of therapy gained weight, BMI, fat mass and total body water, but not lean 
mass (non-fat mass). In contrast, patients who died during TB treatment lost weight, fat mass, lean mass, body water and BMI. 
 
Comparison with previous studies 
 
Previous studies have reported a significant increase in weight in patients with good outcome at the end of TB treatment, 
and a decrease among patients with poor outcome (i.e. those who died) (Bernabe-Ortiz et al., 2011; Hoa et al., 2013; Khan et al., 
2006; Krapp et al., 2008; Vasantha et al., 2014). Approximately 1 kg is lost in the first month of therapy among patients with TB 
who died during treatment, even in patients with MDR-TB (Chung-Delgado et al., 2014). However, these results have been 
obtained mainly from non HIV-infected individuals. Our findings, assessing HIV-infected patients diagnosed with TB follow the 
same trend: a weight loss of 1.8 kg in the first month of therapy, and more than 2.5 kg at the end of the second month. Therefore, 
it seems that weight loss can be also a good predictor of TB treatment outcome among HIV-infected individuals (Kennedy et al., 
1996; Schwenk et al., 2004).  
Our results also expand on previous studies by reporting a reduction in other anthropometric markers (fat mass, lean 
mass, total body water, and BMI) among HIV-infected patients who died during TB treatment. Apparently, weight loss was 
mainly due to fat mass reduction (52.5% in the first month and 53.1% in the second month) instead of lean mass (47.5% in the 
first month and 46.9% in the second month). However, a previous report implies that lean mass reduction can be a better predictor 
of mortality than weight loss (Suttmann et al., 1995). Wasting occurs frequently during HIV infection and increases with disease 
progression. As malnutrition is common among HIV-infected individuals, especially where there is coinfection with TB, 
bioimpedance analysis might be a good approach to prevent deaths among patients with the TB-HIV coinfection (Diouf et al., 
2009).  
Decline in total body water during TB treatment deserves attention. Overall, body water content remains stable during 
adulthood; however, changes in total water have been associated with HIV infection (Diouf et al., 2009). Dehydration might be 
one of the most common consequences derived from a severe disease, but also from malnutrition or inadequate treatment. 
Consequently, participants with a reduction in water should be accurately assessed to determine the potential cause of this, such as 
drug-resistant forms of TB, poor HIV infection management, or concomitant coinfections. On the other hand, BMI reduction was 
also verifiable in coinfected patients who died; however, these results were expected as BMI decline derives from weight 
decrease. 
 
Public health relevance 
 
Our findings corroborate that weight can be a good predictor of TB treatment outcome among HIV-infected individuals. 
Weight measurement, an easy and non-invasive procedure, has been little considered in the past, but currently it has been included 
in many management guidelines (Hoa et al., 2013; MINSA 2013). Some studies have demonstrated that HIV-infected patients 
with TB have a higher prevalence of wasting compared with patients with TB alone (Scalcini et al., 1991). Hhowever, weight 
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variation found in our study was similar to that seen in patients without HIV. A larger study assessed weight loss in HIV-infected 
patients and two different patterns were observed: episodes of acute severe weight loss and episodes of chronic unremitting 
progressive weight loss (Macallan et al., 1993). As a result, our results suggest that a close monitoring of weight and other 
anthropometric markers among HIV-infected patients in tuberculosis treatment is needed, and further studies are required to better 
understand strategies to reduce mortality among these individuals. 
 
Strengths and limitations 
 
Strenghts of this study include the prospective nature of the data collection as well as the use of five different 
anthropometric markers to predict death among HIV-infected patients during TB treatment. However, this study also has some 
limitations. First, data obtained during the first two months of TB therapy only were used in the analysis instead of the total 
treatment duration. A closer monitoring of weight and the other BIA markers (i.e weekly or twice a month) is needed to better 
characterize their variation over time. However, this approach can be justified because the focus of the manuscript was the value 
of these measurements to predict TB treatment outcome, and this prediction is likely to take place at months one and two, when 
patients are routinely assessed according to National Tuberculosis Control Programme guidelines. Secondly, deaths that occurred 
during follow-up might not have been attributable to TB. Nevertheless, 9 out of 17 deaths were in the first two months of 
treatment and it has been suggested that most deaths due to TB occured during the first months of treatment (Mathew et al., 2006). 
Thirdly, variation of anthropometric markers might be due to other comorbidities, not explored in this study. However, changes in 
body composition seen in patients with HIV and TB are very different from those observed in patients with HIV who may suffer 
from lipodystrophy which is characterized by the predominant fat atrophy in the arms and legs, and abdomen fat increase (Carr et 
al., 2003). Finally, whilst we showed a strong correlation, our findings must be verified in a larger prospective study in which 




Our results evidenced that different anthropometric markers might help to predict the progress towards death among 
patients with HIV and TB coinfection. A comprehensive assessment of patients with HIV and TB coinfection must be performed 
to prevent deaths during treatment. Weight change must be evaluated routinely during clinical assessment in order to detect failure 
to respond the treatment and to implement appropriate management strategies for the patient. 
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